Issued by:

Controlled hard copies must be signed and dated by an authorised issuer. Refer to Q-Pulse for approval details.



Page 1 of 9

## Infusion of CAR T cells

### **PURPOSE**

To infuse CAR T cells which are autologous or allogeneic T cells that have been genetically modified to allow them to recognise and kill certain types of cancer. They may be given as a licenced cellular product or within a trial and regulated by MHRA as a type of Advanced Therapy Investigational Medicinal Product (ATIMP).

### RESPONSIBILITY

The consultant responsible for treating CAR T cell eligible patients, Trial Principal Investigator (PI) or Investigator's designee should ensure the patient is eligible to receive the CAR T cell product infusion and ensure the relevant study related pre-infusion investigations, treatments and consent have been performed. It is their responsibility to:

- To confirm the total dose of product to be infused to the patient.
- To ensure the thawing of CAR T cells will be performed by experienced HTL staff who are trained in thawing of cellular therapy products.
- To ensure the infusion of CAR T cells will be performed by experienced BMT CNS staff who
  are trained in infusing of cellular therapy products.

#### RESTRICTIONS

This document should be used in conjunction with trial specific study protocols.

#### **DEFINITIONS**

**CAR T cells** – Chimeric Antigen Receptor T cells

MHRA – Medicines and Healthcare products Regulatory Agency

**ATMP** – Advanced Therapy Medicinal Product

PI - Principle Investigator

**DMSO** – Dimethylsulphoxide Cryoprotectant

N Saline – Sodium Chloride 0.9%

### APPLICABLE DOCUMENTS

HTL/F/131 – request for CAR T cells

HTL/F/125 - request for trial specific cellular products

HTL/O/031 – Thawing and Infusion of Cryopreserved Products

Trial Specific Forms as supplied by the Sponsor

### ITEMS REQUIRED

- 1 x 100ml bag N Saline for IV infusion
- 1 x 500ml bag N Saline
- IV non filter blood infusion set as supplied from Haematology Transplant Laboratory
- 10ml syringes
- Green needles
- CAR T cells as supplied from Haematology Transplant Laboratory
- Chlorphenamine IV 10mg
- Oral paracetamol 1gram
- IV antiemetic choice
- IV N Saline flush
- Sterile Gloves
- Antiseptic wipes

Controlled hard copies must be signed and dated by an authorised issuer. Refer to Q-Pulse for approval details.



Page 2 of 9

- Sterile gloves
- Drip Stand

Issued by:

- Equipment for monitoring BP, pulse and oxygen saturation
- Equipment to deliver oxygen and suction

DETAILS	INFORMATION
PI and trained designees	
<b>1.1.</b> Confirm CAR T cells are available from haematology transplant laboratory	Some patients have sufficient CAR T cells stored for more than single use
<ul> <li>1.2 Confirm with PI/Senior Medical Designee responsible for patient, the dose of CAR T cells for infusion</li> <li>1.3 Check completion time of chemotherapy and calculate time delay required before infusion of CAR T cells considering: <ul> <li>Chemotherapy drugs given</li> <li>Renal function</li> </ul> </li> </ul>	Confirm with PI/Senior Medical Staff, the date for infusion. Most protocols involve chemotherapy and at least 24 hours from completion is required before infusion of CAR T cells. This may be longer depending on which chemotherapy drugs have been given and where there is renal insufficiency
1.4 Ensure delivery of request form to haematology transplant laboratory	HTL/F/131, HTL/F/125 or trial specific prescription paperwork as supplied by sponsor to complete request
1.5 Prescribe IV Chlorphenamine and oral Paracetamol to be administered 30 minutes before infusion of CAR T cells	NO STEROIDS TO BE PRESCRIBED ROUTINELY
	<ul> <li>1.1. Confirm CAR T cells are available from haematology transplant laboratory</li> <li>1.2 Confirm with PI/Senior Medical Designee responsible for patient, the dose of CAR T cells for infusion</li> <li>1.3 Check completion time of chemotherapy and calculate time delay required before infusion of CAR T cells considering: <ul> <li>Chemotherapy drugs given</li> <li>Renal function</li> </ul> </li> <li>1.4 Ensure delivery of request form to haematology transplant laboratory.</li> <li>1.5 Prescribe IV Chlorphenamine and oral Paracetamol to be administered 30 minutes before infusion of CAR T</li> </ul>

# **NOTE**

DO NOT CONFIRM CAR T CELLS FOR DELIVERY TO WARD UNTIL CONDITIONING CHEMOTHERAPY HAS BEEN CONFIRMED COMPLETED AND RENAL FUNCTION HAS BEEN REVIEWED

Issued by:

Controlled hard copies must be signed and dated by an authorised issuer. Refer to Q-Pulse for approval details.



Page 3 of 9

STEP	DETAILS	INFORMATION
	DESIGNATED STAFF INFUSING CA	
2. Inform patient details of CAR T cell infusion	<ul> <li>2.1 Explain procedure for CAR T cell infusion:-</li> <li>Need for two sites for IV access</li> <li>Chlorphenamine and antiemetic to be given IV</li> <li>Oral paracetamol</li> </ul>	Chlorphenamine IV and oral paracetamol to be given 30 minutes before infusion
	<ul> <li>2.2 Explain side effects of DMSO:- <ul> <li>Taste/nausea</li> <li>Smell from DMSO on breath</li> <li>Cough/tickly throat/chest tightness</li> <li>Sedation from chlorphenamine</li> </ul> </li> <li>2.3 Confirm patient understands possibility of cytokine release syndrome, requirement for ITU and possible neurological effects</li> </ul>	Similar to tinned tomatoes/sweetcorn  Contact PI or designee if patient needs further information/discussion
3. Prepare for infusion of CAR T cells	<ul> <li>3.1 Check patient is ready for CAR T cell infusion:-</li> <li>Check correct patient is at bed area</li> <li>Enquire if nausea/vomiting</li> <li>Check two good IV access sites are available</li> </ul> 3.2 Prepare sterile tray with:-	Confirm full name, D.O.B, and hospital number with hospital notes of patient Check time of last antiemetic dose Check re allergies Central line flushes easily or insert peripheral venous access minimum 18 gauge for infusion of CAR T cells Second access site should be available in case of adverse
	<ul> <li>1 x 100ml bag N Saline</li> <li>1 x 500 ml bag N Saline</li> <li>IV blood component giving set</li> <li>IV Chlorphenamine</li> <li>IV antiemetic if required</li> <li>Normal saline flush</li> <li>10ml syringes</li> <li>Green needles</li> <li>Sterile gloves</li> <li>Antiseptic wipes</li> <li>Sterile gloves</li> <li>Sterile gloves</li> </ul>	effects  IV non filter blood giving set to be supplied from Haematology Transplant Laboratory on delivery of CAR T cells. For Autolus study please see appendix with additional items required to flush CAR T product bag after product infusion

ACLIN.O.006 Version: 1.5 lssued by: Date:

Controlled hard copies must be signed and dated by an authorised issuer. Refer to Q-Pulse for approval details.



Page 4 of 9

STEP	DETAILS	INFORMATION
	<ul> <li>3.3 Record baseline observations on neurological NEWS chart</li> <li>Pulse</li> <li>Blood pressure</li> <li>Temperature</li> <li>Oxygen saturation</li> <li>Baseline neurological assessment</li> </ul>	
	3.4 Give oral paracetamol	Administer 30 minutes before infusion
	<b>3.5</b> . Give IV Chlorphenamine and antiemetic as appropriate	Administer 30 minutes before infusion
	<b>3.6</b> Spike 100ml N Saline bag with infusion IV giving set	Check N Saline can flow freely. If not, establish new access before giving CAR T cells.

# **NOTE**

Cryopreserved CAR T cells should be infused essentially in under thirty minutes since defrosting. Small gauge access may block during infusion. Access in hand/forearm may flow too slowly.

Issued by:

Controlled hard copies must be signed and dated by an authorised issuer. Refer to Q-Pulse for approval details.



Page 5 of 9

STFP	DETAILS	INFORMATION
4. Infuse CAR T cells	<ul> <li>4.1 Request haematology transplant laboratory staff to defrost a bag of CAR T cells.</li> <li>4.2 Check identity of patient with identification of CAR T cell bag.</li> <li>Ask patient to give name</li> <li>Ask patient to give date of birth</li> <li>Check against hospital notes, wristband, CAR T cell bag</li> <li>Check patient identification detail on</li> </ul>	2 person checks with medical staff, nursing staff or stem cell laboratory staff.
	<ul> <li>bag corresponds with hospital notes</li> <li>Check bag detail corresponds with Request for Trial Specific Cellular Products form or CAR T cell request form</li> </ul>	HTL/F/125 or HTL/F/131
	<ul> <li>4.3 Stop N Saline infusion, disconnect and insert spike of giving set into CAR T cell bag port</li> <li>4.4 Infuse initially slowly to observe reaction and provided stable increase to infuse over 5 to 15 minutes</li> </ul>	For small volumes of CAR T cells in patients weighing <50kg it may be preferred to draw all the CAR T cell bag contents into a syringe for direct administration over 5 to 10 minutes. Flush bag with N Saline to ensure all product
	<b>4.5</b> Once almost completed, request any further bag of CAR T cells for defrost if available and patient has not had adverse reaction to first bag	Once a bag is defrosted it must be infused within 30 minutes
	<b>4.6</b> Once CAR T cell bag is empty, continue to next bag NOTE: for Autolus product, each bag must be flushed in addition to the infusion set. See appendix.	Do not request thaw of further bags if patient unwell or technical issues with infusion Repeat identification checks in 4.2 with each bag given
	<ul> <li>4.7 Once all requested bags infused attach 500 ml IV N Saline to clear line or for Autolus product, refer to appendix</li> <li>4.8 Flush patient IV access with N Saline if remaining in situ</li> </ul>	Continue IV infusion with N Saline until line is as clear as possible.
	<b>4.9</b> Complete paperwork by signing receipt on request form and completing accompanying trial specific forms	HTL/F/125 Trial specific paperwork

Issued by:

Controlled hard copies must be signed and dated by an authorised issuer. Refer to Q-Pulse for approval details.



Page 6 of 9

STEP	DETAILS	INFORMATION
5. Observe patient during infusion	5.1 Consider volume intake  5.2. Symptoms:	For mild reactions slow infusion and  Nausea vomiting – second line antiemetics eg cyclizine or prochlorperizine  Rigor/headache – consider Pethidine 12.5 to 25mg IV  Hives/pruritis – consider further chlorphenamine  In the event of severe reaction call for medical assistance and advise patient consultant, PI or designees Emergency anaphylactic reaction which may cause stridor, wheeze, facial swelling, colour change, chest pain, tachycardia, hypotension, abdominal cramps – stop infusion, administer oxygen, N saline, consider adrenaline, chlorphenamine, hydrocortisone, salbutamol nebuliser.

## **NOTE**

DAMAGE TO A CAR T CELL BAG WITH RISK OF LEAK OF PRODUCT CAN OCCASIONALLY OCCUR USUALLY WHEN INSERTING GIVING SET. DO NOT REMOVE GIVING SET AND COVER DAMAGE WITH A STERILE SWAB. CELLS CAN OFTEN BE RECOVERED BY HAEMATOLOGY TRANSPLANT LABORATORY STAFF DRAWING INTO A 50 ML SYRINGE. CONTACT CONSULTANT/PI/DESIGNEE AND REFER TO TRIAL SPECIFIC MANAGEMENT PLAN FOR ADVICE TO ADMINISTER. SAVE AN ALIQUOT TO SEND FOR MICROBIOLOGY. CONSIDER ANTIBIOTIC COVER. REPORT AS DATIX. REPORT TO MANUFACTURER.

6. Dispose of waste	<ul><li>6.1 For licensed products please dispose of clinical waste according to Trust policy</li><li>6.2 For unlicensed product please dispose of all clinical waste according to Appendix</li><li>10</li></ul>	
7. Record infusion of CAR T cells	<ul> <li>7.1 Complete HTL/F/125 or HTL/F/131 and copy to patient notes with original to Haematology Transplant Laboratory</li> <li>7.2 Document procedure in hospital notes</li> <li>7.3 Complete trial specific paperwork</li> </ul>	In the event of any incident or adverse event/ reaction this should be reported to PI/designee and DATIX within 24 hours. Additionally report to sponsor as specified in trial protocol /yellow card

Controlled hard copies must be signed and dated by an authorised issuer. Refer to Q-Pulse for approval details.



Page 7 of 9

## 8. Further Information/Exceptions

Issued by:

Refer to trial specific management plans.

In the unlikely situation of the DMSO dose exceeding 1ml DMSO/kg body weight the Pl/designee should consider splitting the dose between early morning and late afternoon.

9. For further information refer to: Quality Management Staff QMU.I.021

Page 8 of 9

## Appendix I

## Additional information to flush the product bag

- 1) Cellular Therapies will issue:
  - Needle free coupler
  - BAXTER non-filtered infusion set
  - Plasma transfer set
  - ATIMP
- 2) Spike 500ml N Saline for flushing the product bag with a needle free coupler
- 3) Clamp a plasma transfer set
- 4) Attach the luer lock of the plasma transfer set to the needle free coupler in the saline bag
- 5) Spike the ATIMP product bag with the free needle free coupler end of the plasma transfer set
- 6) Clamp the Baxter infusion set using the roller clamp
- 7) Spike the ATIMP product bag with the Baxter infusion set
- 8) Release the roller clamp on the Baxter infusion set and administer entire contents product bag
- 9) Clamp the Baxter infusion set using the roller clamp
- 10) Release the clamp on the plasma transfer set and flush 25mL of saline into the ATIMP product bag
- 11) Clamp the plasma transfer set
- 12) Flush the bag by gently mixing the saline around the product bag
- 13) Release the roller clamp and administer contents of the bag
- 14) Repeat points 10-14 two more times

Controlled hard copies must be signed and dated by an authorised issuer. Refer to Q-Pulse for approval details.



## Appendix II

## Appendix for Waste disposal for unlicensed CAR T cell products

- Prepare waste disposal as follows:
  - Put the giving set with spike still within the empty product bag and saline bag, any
     cannula if removed and any additional product bags into a clinical waste container/bag
  - Seal the container/bag
  - Label as 'CAR-T (GM class 1) waste'
- Contact microbiology to say there is CAR T GM waste for disposal by phoning 31019
- Waste container taken to main pathology Reception.
  - Waste should be handed to microbiology staff, Graham Short, Robert Oxley, Michael Jones.
- Waste autoclaved in Microbiology